Replies to post #123981 on Biotech Values

[NP1986]

The other advantage of Btripla vs Atripla: Edurant is Pregnancy Category B (no known risk), while Sustiva is Pregnancy Category D (empirical evidence of fetal risk).

Ah, thanks for pointing out the pregnancy advantage. I wasn't aware of this.

Do you see this being a viable niche market for Btripla? From what I gather, Combivir is still being used for pregnant women, although I've not seen a breakdown of market share in this population.